Innovative Medicine

We are driven by a bold vision to eliminate cancer

At Johnson & Johnson Innovative Medicine (J&J), we innovate with purpose to lead where medicine is going. We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day eliminate this disease.

With more than three decades of history in oncology our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in haematologic malignancies and solid tumours is stronger than ever.

Learn more

Our focus in immunology

Johnson & Johnson Innovative Medicine (J&J) understands how distressing and debilitating immune-mediated inflammatory diseases can be, which is why we innovate with purpose to lead where medicine is going.

Our goal is to improve diagnosis, patients’ access to the best possible treatments and continue to provide new and better medicines.

Learn more

Our focus in haematology

At Johnson & Johnson Innovative Medicine (J&J) we have come a long way in progressing the treatment of people diagnosed with blood cancers over the past 20 years. With more than three decades of history in oncology, our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in haematology is stronger than ever.

Our leadership has advanced transformative therapies for haematologic malignancies, and we are committed to continuing to lead in the evolution of our understanding and treatment of these diseases.

Learn more

Our focus in pulmonary hypertension

At Johnson & Johnson Innovative Medicine (J&J) UK, our focus is on Pulmonary Arterial Hypertension (PAH) — a specific, rare form of PH.

We are spearheading a new era for those living with PAH to transform the disease into a long-term manageable condition, so that patients can live fulfilling lives.

Learn more

Our focus in specialty ophthalmology

At Johnson & Johnson Innovative Medicine (J&J) UK, we are committed to advancing the treatment of retinal diseases that cause vision loss and impairment. This includes inherited retinal diseases (IRDs) and age-related macular degeneration (AMD), each presenting unique challenges and unmet needs.

At J&J, we focus on addressing these challenges through innovative therapies and strong partnerships with healthcare professionals. Our research into gene therapies and novel treatments aims to improve patient outcomes, ease the burden on healthcare services, and help patients preserve their vision and quality of life.

Learn more

Our focus in neuroscience

At Johnson & Johnson Innovative Medicine (J&J) UK, we are at the forefront of neuroscience. We are dedicated to developing precise and impactful treatment options that alleviate the burden of nervous system disorders.

Our goal is to enhance the quality of life for patients affected by neurological conditions in the UK. We aim to do this through an expanded, differentiated pipeline that enhances our portfolio of novel products aimed at treating and preventing nervous system disorders.

Through our in-house discovery, strategic partnerships and acquisitions, we are transforming our approach to understanding and treating these complex conditions.

Learn more

Our focus in precision medicine

Our bold vision for precision medicine is to ensure that every person living with advanced cancer has access to the most effective, personalised treatment available.

At Johnson & Johnson Innovative Medicine (J&J) UK, we are leading the way in realising the potential of precision medicines by building trusted partnerships with the NHS and other stakeholders, removing barriers to testing, and supporting access to tailored care – in oncology and beyond.